Xylyx Bio has reported data from an independent clinical trial which demonstrated that its Matrikynes ingredient significantly enhanced the structure, function and appearance of skin.
Matrikynes’ safety has been validated by the study and proved its efficacy for anti-ageing and other topical skin applications.
Matrikynes, which is developed via biomedical research, features a mixture of natural extracellular matrix-derived peptides known as matrikines.
The intrinsic bioactivity of matrikines enabled the activation of regenerative mechanisms for tissue repair, as well as reversing the effects of ageing.
The independent study involved 56 female volunteers aged between 35 and 65 years with different skin types and tones for the assessment of the clinical safety and efficacy of Matrikynes for topical skin applications.
Using clinical instrumentation and validated measurement techniques, standard dermatological assessments have been performed for the volunteers.
According to the company, the topical application of Matrikynes demonstrated a better clinical safety profile and several significant improvements in the structure, function, and appearance of ageing and damaged skin.
The study reported no allergic sensitisation or irritant reaction to Matrikynes, and significant improvement was observed in skin barrier repair.
Matrikynes also helped improve skin density, and reduced the appearance of global fines lines and deep wrinkles.
Xylyx Bio chief scientific officer Dr John O’Neill said: “As a pioneer in regenerative medicine, Xylyx Bio developed Matrikynesin response to the increasing demand in topical skincare for evidence-based ingredients that can effectively address skin damage and ageing.
“This study confirms that Matrikynesis safe and offers multiple functional and cosmetic benefits. Such significant reparative capabilities in a single ingredient pave the way for a new paradigm of regenerative skincare.”
